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Abstract 
Background: Cardioprotective value of ischemic post- (IPostC), remote (RIC) conditioning in acute myocardial infarc-
tion (AMI) is unclear in clinical trials. To evaluate cardioprotection, most translational animal studies and clinical trials 
utilize necrotic tissue referred to the area at risk (AAR) by magnetic resonance imaging (MRI). However, determination 
of AAR by MRI‚ may not be accurate, since MRI-indices of microvascular damage, i.e., myocardial edema and microvas-
cular obstruction (MVO), may be affected by cardioprotection independently from myocardial necrosis. Therefore, we 
assessed the effect of IPostC, RIC conditioning and ischemic preconditioning (IPreC; positive control) on myocardial 
necrosis, edema and MVO in a clinically relevant, closed-chest pig model of AMI.
Methods and results: Acute myocardial infarction was induced by a 90-min balloon occlusion of the left anterior 
descending coronary artery (LAD) in domestic juvenile female pigs. IPostC (6 × 30 s ischemia/reperfusion after 90-min 
occlusion) and RIC (4 × 5 min hind limb ischemia/reperfusion during 90-min LAD occlusion) did not reduce myo-
cardial necrosis as assessed by late gadolinium enhancement 3 days after reperfusion and by ex vivo triphenyltetra-
zolium chloride staining 3 h after reperfusion, however, the positive control, IPreC (3 × 5 min ischemia/reperfusion 
before 90-min LAD occlusion) did. IPostC and RIC attenuated myocardial edema as measured by cardiac T2-weighted 
MRI 3 days after reperfusion, however, AAR measured by Evans blue staining was not different among groups, which 
confirms that myocardial edema is not a measure of AAR, IPostC and IPreC but not RIC decreased MVO.
Conclusion: We conclude that IPostC and RIC interventions may protect the coronary microvasculature even with-
out reducing myocardial necrosis.
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Background
Despite the wide availability of advanced revasculariza-
tion techniques, acute myocardial infarction (AMI) is 
one of the leading causes of mortality and morbidity in 
developed countries [1]. Preclinical studies of various 
ischemic conditioning techniques have shown promising 
results in the reduction of AMI-related cardiac damage 
(see for an extensive recent review: [2]). Ischemic precon-
ditioning (i.e., brief cycles of ischemia and reperfusion of 
the involved coronary artery before sustained ischemia; 
IPreC) was shown first to attenuate subsequent myocar-
dial damage [3]. Since then, it has been demonstrated 
that ischemic conditioning reduces myocardial ischemia/
reperfusion injury (IRI) if applied after cardiac ischemia 
(ischemic postconditioning; IPostC), which is more fea-
sible for clinical application [4]. Moreover, cardioprotec-
tion could be elicited by applying ischemic stimuli on a 
distant area of the heart or on a remote organ (e.g., kid-
ney, skeletal muscle) termed remote ischemic condition-
ing (RIC) [5]. Both IPostC and RIC have been reported 
to be cardioprotective in preclinical [5] and clinical [6–9] 
settings. However, to date, the largest clinical trials in 
IPostC did not show any benefit of IPostC on ST-eleva-
tion myocardial infarction patients after primary per-
cutaneous intervention (POST and DANAMI 3-iPOST 
trial) in terms of long-term outcome [10, 11]. So far, a 
small-scale clinical trial involving ST-elevation myocar-
dial infarction (STEMI) patients has been completed 
and demonstrated long-term efficacy of RIC as assessed 
by significant improvement of major adverse cardiac 
and cerebrovascular events [12]. Nevertheless, two large 
clinical trials reported that RIC did not improve the long-
term outcome after cardiac surgery (ERICCA [13] and 
RIPHEART [14] trials).
The cardioprotective efficacy of an intervention is 
assessed by different methods in preclinical settings 
and in clinical trials. For instance, there is no accurate 
and widely available method to measure the area at risk 
(AAR; the area excluded from the coronary circulation), 
which is the basis of preclinical cardioprotective studies. 
Although it has been proposed that myocardial edema by 
T2-weighted magnetic resonance imaging (MRI) corre-
lates well with histopathology-based evaluation of AAR 
[15], it has been demonstrated that myocardial edema 
correlates better with the myocardial necrosis than with 
the AAR [16]. Furthermore, efficacy of interventions in 
(pre)clinical studies are almost exclusively based on the 
measurement of myocardial necrosis by assessing infarct 
size or necroenzyme release, which primarily represents 
the decay of cardiac myocytes, and which are major 
determinants of the outcome of AMI according to clini-
cal studies [17]. However, damage to other cell types of 
the heart, such as the coronary microvasculature may 
also contribute to the IRI [2, 18]. For instance, myocardial 
edema [19], microvascular obstruction (MVO; ischemic 
area, where myocardial perfusion is not restored despite 
successful revascularization) [20], endothelial dysfunc-
tion, and microembolisation are major signs of microvas-
cular damage [21].
Therefore, we studied the effects of IPostC and RIC 
by comparing them to the effects of the positive control 
(IPreC) on measures of IRI (myocardial necrosis, edema 
and MVO) as determined by in  vivo MRI and ex  vivo 
histological staining in a clinically relevant, closed-chest 
swine model of AMI.
Methods
Experimental design (Fig. 1) 
Domestic female pigs (25–35  kg; genotype: DanBred 
hybrid, purchased from the University of Kaposvár, 
Hungary) were kept according to the Big Dutchman 
principles. The animals were fed with a pregnant sow 
diet containing a low energy and balanced protein level 
produced by Dalmand co. Ltd. They further underwent 
regular veterinarian check-ups, and only healthy animals 
were selected for the study. Furthermore, before percuta-
neous intervention, transthoracic echocardiography, and 
angiography was served as a baseline screening method 
to exclude animals with abnormal coronary anatomy or 
myocardial disease.
The pigs were block randomized [22] into four groups: 
ischemia only (Isch; n  =  17), IPreC (n  =  12), IPostC 
(n =  14) and RIC (n  =  17). Three animals died during 
myocardial ischemia (Isch: 1; IPreC: 1; IPostC: 0; RIC: 1) 
and 4 during reperfusion due to therapy resistant malig-
nant ventricular rhythm disturbances (Isch: 2; IPreC: 1; 
IPostC: 1; RIC: 0). Additionally, 3 animals were excluded 
due to procedural technical reasons. The final case num-
bers were 14, 9, 12 and 14 in Isch, IPreC, IPostC and 
RIC groups, respectively. According to the current ESC 
STEMI guidelines [23, 24], the pigs were pretreated with 
loading doses of 250 mg acetyl salicylic acid and 300 mg 
clopidogrel with maintenance doses of 100 and 75 mg pro 
day, respectively. Although 600  mg dose of clopidogrel 
has been shown to superior over a 300 mg dose in myo-
cardial necrosis reducing effects [25], our experimental 
Keywords: Ischemic preconditioning, Ischemic postconditioning, Remote conditioning, Myocardial edema, Area at 
risk, Ischemia/reperfusion injury
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protocol has been planned to minimize the effect of 
possible confounding factors such as clopidogrel [26]. 
Animals were sedated with 12  mg/kg ketamine hydro-
chloride, 1  mg/kg xylazine, and 0.04  mg/kg atropine 
intramuscularly after an overnight fast. Anesthesia was 
induced by inhalation of isoflurane (2–2.5 vol%). Animals 
were intubated endotracheally and anesthesia was main-
tained by inhalation of an isoflurane oxygen mix (2–2.5 
vol% and 3  L/min). Magnesium sulphate (4.06  mEq 
diluted in 10  mL, in every 60  min) and a continuous 
amiodarone infusion (300  mg diluted in 500  mL saline) 
were being administered throughout the procedure via 
an ear vein. Sheaths were inserted into femoral artery 
and femoral vein to further have entry routes for the 
catheterization, and 5000–5000  IU heparin was admin-
istered via each sheath. Cardiac function was assessed 
with echocardiography. Baseline hemodynamics were 
recorded, and selective angiography of the left coronary 
artery was performed. After the analysis of the baseline 
angiogram, a balloon catheter (2.75 mm diameter, 8 mm 
length) (Abbott Vascular) was placed in the mid part of 
the left anterior descending coronary artery (LAD) after 
the origin of the 2nd diagonal branch. For induction of 
AMI, the intracoronary balloon was inflated with 5 atm 
for 90  min, followed by deflation of the balloon, result-
ing in reperfusion (3  h or 3  days) which was confirmed 
by coronarography. In IPreC group, LAD was occluded 
by the inflation of the balloon at 5 atm 3 times for 5 min 
followed by 5 min of reperfusion, while in other animals 
the balloon was left deflated for 30 min [27]. Then LAD 
was occluded by inflating coronary balloon, which was 
confirmed by coronarography. RIC was performed by 4 
cycles of 5  min occlusion and 5  min reperfusion of the 
femoral vessels by tightening and releasing of a snare 
around the right hind limb starting at the 50th min of 
LAD occlusion [9]. We verified the hind limb ischemia 
in three ways: (1) Apparent lividity during ischemia and 
pronounced hyperemia during reperfusion was observed 
distal to the occlusion. (2) In each animal, a superficial 
femoral artery was cannulated distal to the occlusion, 
and blood pressure was measured during the interven-
tion. The minimum of 30/30 mmHg blood pressure was 
achieved while the wire was tightened around the hind 
limb. (3) In one particular animal, we performed a fem-
oral angiography before and during hind limb ischemia 
as well [Additional file  1: Video_S1.avi (before), Addi-
tional file  2: Video_S2.avi (during hind limb ischemia)]. 
IPostC was initiated within 1  min after the termination 
of 90-min index ischemia and was performed by apply-
ing 6 cycles of 30/30  s LAD occlusion and reperfusion 
[28]. The interventional cardiologist was not blinded dur-
ing the investigation due to the nature of the procedure: 
IPreC and IPostC were achieved by inflating a balloon 
in the LAD, which required an unblinded interventional 
cardiologist. Nonetheless, the interventional cardiologist 
was not aware of the allocation until the initiation of the 
experimental intervention (e.g. right after balloon defla-
tion if the animal was in IPostC group). After reperfusion 
was initiated 5000  IU heparin was given intracoronary. 
Final reperfusion was confirmed with coronarogra-
phy and the catheters were removed. Ten min after the 
initiation of reperfusion, the hemodynamic data was 
recorded again. Anesthesia was either maintained for 3 h 
or in case of 3 days reperfusion, wounds were closed and 
anesthesia was terminated by the withdrawal of isoflu-
rane. Analgesia was applied by intramuscular injections 
of 1  g metamizole. An antibiotic cocktail (100  mg ben-
zathine benzylpenicillin, 100 mg procaine benzylpenicil-
lin, 200 mg dihydrostreptomycin-sulphate) was given i.m. 
before recovery.
Measurement of myocardial necrosis, edema and MVO 
by cardiac MRI
The amount of myocardial necrosis and MVO were 
determined by acquiring late gadolinium-enhanced 
images (gold standard method) [9, 29]. Dark blood pre-
pared IR-TSE sequence single slice breath-hold acquisi-
tion T2w protocol was used to detect myocardial edema 
[9, 29]. 3 days (70–78 h) after the deflation of the balloon 
in LAD, anesthesia was induced by inhalation of an iso-
flurane-oxygen mix. Prior to the cardiac MRI, atracurium 
was administered and ventilation was maintained with 
mechanical ventilation. For the assessment of myocar-
dial necrosis and edema, cardiac MRI was performed 
using a 1.5T clinical scanner (Avanto, Siemens) using a 
phased array coil and a vector ECG system. Cine MRI 
images was acquired using a retrospectively ECG-gated, 
steady-state free precession cine MRI technique (Cin-
etruefisp sequence) in short-axis and long-axis views of 
the heart using 1.2 ms echo time, 40 ms repetition time, 
65° flip angle, 15 segments, 360 mm field-of-view, 8 mm 
slice thickness, and 256 × 256 image matrix. The image 
resolution was 1.4 ×  1.4 ×  8  mm. T2-weighted cardiac 
MRI was performed by short inversion time inversion 
recovery dark blood technique with single slice breath-
hold acquisition and inversion recovery preparation 
(TI =  170  ms; 15 segments; every second trigger pulse; 
TE 74  ms, flip angle 180°). The slice position and reso-
lution was identical as cine images. The late gadolinium-
enhanced images were acquired to determine the amount 
of myocardial necrosis and MVO. A 2-dimensional single 
shot Truefisp sequence with non-selective IR pulse shift 
acquisition to a diastolic phase of the cardiac cycle by 
adjusting the TR was used 12–15  min after administra-
tion of a gadolinium-based contrast agent (0.13  mmol/
kg gadobutrol, Gadovist 1.0  mmol, Bayer), with slice 
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positions identical to the cine images. Typical in-plane 
resolution was 1.4 × 1.4 × 8 mm (echo time 1.2 ms, flip 
angle 50°, triggering to every other heart beat). The inver-
sion time was set to null the signal of viable myocardium 
and ranged from 280–320 ms. Left and right ventricular 
end-diastolic and end-systolic volumes, stroke volumes, 
ejection fractions, and masses were quantified using 
manual planimetry of end-diastolic and end-systolic 
short-axis SSFP cine images with MASS 7.6 analysis soft-
ware (Magnetic Resonance Analytical Software System, 
Medis Medical Imaging Software, Leiden, The Nether-
lands). Myocardial necrosis and edema were quantified 
after manual planimetry both on the delayed contrast 
enhancement and T2-weighted images by delineation of 
myocardium with signal intensity 4 SDs above the mean 
signal obtained in the remote noninfarcted myocar-
dium using MASS 7.6 analysis software. If present, the 
hypointense zone in the center of the hyperenhancement 
(MVO) was quantified and added to the infarct volume as 
previously described [30]. Values were expressed relative 
to the left ventricular mass. The measurement of MVO 
with late gadolinium enhancement closely correlates with 
myocardial contrast echocardiography, angiographic and 
invasive indices used for the assessment of MVO [31]. 
Moreover, late-gadolinium enhancement correlates with 
the histological measurement of MVO as demonstrated 
by Zalewski et al. [29].
Myocardial necrosis and AAR measurement by ex vivo 
staining
Hearts were removed from the chest, and placed imme-
diately in ice-cold saline 3 h after reperfusion. LAD was 
reoccluded, ex  vivo at the same place as in  vivo (prior 
to the obduction, coronary angiography of the pig was 
reviewed, and the occlusion site was identified.), and 
Evans blue (Sigma) was injected into the coronary arter-
ies through their orifices to negatively stain the AAR [29, 
32]. 10 mm slices were then cut and incubated in 1% tri-
phenyltetrazolium chloride (TTC, Sigma) at 37  °C for 
15 min to stain viable areas. After overnight fixation with 
4% formalin, slices were weighed and scanned for blind 
planimetric analysis (InfarctSize 2.4b software; Pharma-
hungary Group). AAR was expressed relative to the left 
ventricular (LV) mass, and myocardial necrosis relative 
to the AAR mass.
Coronary angiography and AAR calculation
All animals underwent coronary angiography accord-
ing to the protocol established by the catheterization 
laboratory. Anterograde flow in the artery before and 
after balloon inflation was characterized using the TIMI 
(Thrombolysis in Myocardial Infarction) system [33]. 
TIMI myocardial perfusion grade and myocardial blush 
grade were assessed visually on the angiogram and made 
by expert interventional cardiologist, and all data were 
entered prospectively into a database. Myocardial blush 
grade has been defined as follows: 0, no myocardial blush 
or contrast density; 1, minimal myocardial blush or con-
trast density; 2, moderate myocardial blush or contrast 
density but less than that obtained during angiography of 
a contralateral or ipsilateral non–infarct-related coronary 
artery; and 3, normal myocardial blush or contrast den-
sity, comparable with that obtained during angiography 
of a contralateral or ipsilateral non–infarct-related coro-
nary artery. When myocardial blush persisted (“stain-
ing”), this phenomenon suggested leakage of contrast 
medium into the extravascular space and was graded 0 
[34, 35]. No digital techniques were used. The AAR was 
established by using the modified APPROACH score 
[36].
Transthoracic echocardiography
Two-dimensional, M-mode and Doppler echocardio-
graphic examinations were performed in accordance 
with the criteria of the American Society of Echocardi-
ography with a Vivid i portable ultrasound system (Gen-
eral Electric Medical Systems) using a phased array 
2.7–8 MHz transducer (6S-RS probe). Data of three con-
secutive heart cycles were analysed (EchoPac Dimension 
software; General Electric Medical Systems) in a blinded 
manner. The mean values of three measurements were 
calculated and used for statistical evaluation.
Statistics
Values were expressed as mean  ±  standard error of 
mean. Statistical analyses were done by using one way or 
repeated measures ANOVA with LSD or Dunnett’s post 
hoc test and Kruskal–Wallis test as indicated (IBM SPSS 
Statistics, Version 19). To limit the case numbers in the 
cardiac MRI study, one-way ANOVA was performed by 
using bootstrapping with 1000-sample replacement [37], 
as frequently used in clinical studies [38–40] and recom-
mended for preclinical studies as well [41]. Statistical sig-
nificance was accepted if the p value was below 0.05.
Results
Myocardial necrosis, edema and MVO by cardiac MRI
To quantify myocardial necrosis, edema and MVO, car-
diac MRI was performed 3 days after coronary occlusion 
and reperfusion. Myocardial necrosis (% of LV) was not 
affected by IPostC and RIC (n = 7, and 8, respectively), 
however, IPreC (n = 4) attenuated it significantly as com-
pared to the Isch group (n =  7), although only 4 IPreC 
cases were studied with MRI (Fig. 2a). Myocardial edema 
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(% of LV) was significantly decreased by IPostC and 
RIC (n = 9, and 7, respectively) as compared to the Isch 
group (n = 7), however, only a tendency of decrease was 
observed by IPreC (n = 4; p = 0.06; Fig. 2b). At baseline, 
hemodynamic parameters were not significantly differ-
ent between groups, whereas at reperfusion heart rate 
was significantly lower in IPreC and RIC groups as com-
pared to the Isch group (Table 1). AAR based on angio-
graphic score was not different between groups (Table 2). 
Furthermore, angiographic measures of reperfusion, i.e., 
TIMI score, myocardial blush grade, and TIMI myocar-
dial perfusion grade were not affected by conditioning 
stimuli (Table  2). MVO volume (% of LV) was signifi-
cantly decreased by IPreC and IPostC (n  =  4, and 7, 
respectively), but not by RIC (n = 8) as compared to the 
Isch group (n = 7) (Fig. 2c).  
Myocardial necrosis and AAR evaluated by ex vivo staining
To assess myocardial necrosis and AAR by an ex vivo his-
tological method, the gold standard TTC and Evans blue 
staining were applied after 3 h of reperfusion. IPostC and 
RIC did not decrease myocardial necrosis (n = 5, and 5, 
respectively) (% of AAR), however, IPreC (n = 6), signifi-
cantly decreased it as compared to the Isch group (n = 5) 
(Fig.  3a). There was no difference in AARs between the 
experimental groups (% of LV) as evaluated by Evans blue 
staining (Fig. 3b).
Myocardial function by cardiac MRI and echocardiography
Myocardial function was analyzed by cardiac MRI and 
echocardiography. Myocardial function was not different 
between groups after either 3 h or 3 days of reperfusion 
(Tables 3, 4, 5).
Fig. 1 Experimental protocol. Isch ischemia only, IPreC ischemic preconditioning, IPostC ischemic postconditioning, RIC remote ischemic condition-
ing, LAD left anterior descendent coronary artery, TTC triphenyl tetrazolium chloride, MRI magnetic resonance imaging
(See figure on next page.) 
Fig. 2 The effect of IPreC, IPostC and RIC on myocardial necrosis (a; n = 4–8/group), edema (b; n = 4–9/group) and MVO (c; n = 4–8/group) size 
as evaluated with cardiac MRI. d-e Representative MRI images of myocardial necrosis and edema. Green line: apicardial outline, red line: endocardial 
outline, red area: myocardial necrosis, dark blue area: MVO, light blue area: myocardial edema. *p < 0.05 vs. Isch. Isch ischemia only, IPreC ischemic 
preconditioning, IPostC ischemic postconditioning, RIC remote ischemic conditioning, MRI magnetic resonance imaging, LV left ventricle, MVO 
microvascular obrstruction
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Discussion
Here we studied the effect of IPostC and RIC on 
IRI-related MRI parameters in a clinically relevant, 
closed-chest porcine model of reperfused AMI and dem-
onstrated that IPostC and RIC protected the microvas-
culature against IRI, as they reduced myocardial edema, 
and IPostC decreased MVO. However, IPostC or RIC 
did not reduce myocardial necrosis, although the posi-
tive control IPreC reduced it. This is the first comparative 
demonstration of the variable effects of different condi-
tioning maneuvres on IRI-related MRI parameters, and 
that myocardial edema and MVO change independently 
from myocardial necrosis. Our results support findings 
of clinical trials that myocardial edema may change due 
to various interventions and it does not represent AAR.
The translation of cardioprotective conditioning stim-
uli into the clinical practice has been proven difficult 
and disappointing despite numerous positive proof-
of-concept clinical trials [18]. The neutral results have 
been attributed to many factors, such as recruitment of 
inadequate patient population, type of revasculariza-
tion, inclusion of late revascularizations, comorbidities 
and comedications [18]. Moreover, the strict adherence 
to certain endpoints, such as myocardial infarct size and 
the neglect of the microvasculature might also hinder 
the successful translation of various cardioprotective 
strategies [21]. Here we demonstrated with ex vivo Evans 
blue staining and in vivo angiography scoring that AAR 
was not affected by conditioning stimuli, while myocar-
dial edema was significantly decreased by both IPostC 
and RIC indicating that the extensive damage of the 
cardiac microvasculature was prevented. Similarly, two 
clinical trials showed that myocardial edema is attenu-
ated by IPostC [6] or RIC [9], however, others reported 
otherwise (IPostC: [42, 43]; RIC: [8, 43]). These results 
indicate that edema might be independent from AAR in 
cardioprotection studies, therefore, applying myocardial 
edema as AAR may lead to false conclusions in clini-
cal trials. To date, no clinical trial has been conducted 
to reveal the prognostic role of myocardial edema in 
ST-segment elevation AMI, although it has been shown 
that non-STEMI patients with myocardial edema had 
higher mortality [44]. However, it is well-established 
that the volume or even the presence of MVO, another 
clinically detectable marker of microvascular injury, cor-
relates with long-term outcome of AMI (see for review 
[20]). In our present experimental model, IPostC, but 
not RIC, reduced MVO. Similarly to our findings, it 
has been reported in a clinical trial that IPostC reduces 
MVO [45], however, no other clinical trials confirmed 
the MVO-reducing ability of either IPostC [42, 43] or 
RIC [9, 43]. Nevertheless, the assessment of myocar-
dial edema and MVO in preclinical and clinical studies 
may provide additional valuable indices. In our present 
study, we observed that myocardial function was not dif-
ferent between groups after reperfusion, although IPreC 
Table 1 Hemodynamic data
* p < 0.05 vs. Isch. n = 4–13/group
Isch ischemia only, IPreC ischemic preconditioning, IPostC ischemic postconditioning, RIC remote ischemic conditioning, HR heart rate, SBP systolic blood pressure, DBP 
diastolic blood pressure, MABP mean arterial blood pressure
Baseline Reperfusion 10 min
HR (1/min) SBP 
(mmHg)
DBP 
(mmHg)
MABP 
(mmHg)
dP/dt
(mmHg/s)
HR (1/min) SBP 
(mmHg)
DBP 
(mmHg)
MABP 
(mmHg)
dP/dt
(mmHg/s)
Isch 109.5 ± 5.2 112.6 ± 5.9 69.3 ± 4.6 87.4 ± 5.1 1037 ± 81 130.2 ± 5.1 93.6 ± 6.4 54.1 ± 4.0 71.1 ± 4.6 800 ± 54
IPreC 90.6 ± 9.4 102.0 ± 10.8 65.5 ± 8.1 82.6 ± 7.2 838 ± 141 92.4 ± 14.4* 82.2 ± 4.4 53.8 ± 4.7 63.4 ± 3.8 560 ± 196
IPostC 103.7 ± 5.2 117.7 ± 7.3 74.4 ± 5.1 92.2 ± 6.0 968 ± 110 116.8 ± 6.1 93.3 ± 5.0 50.4 ± 2.2 68.1 ± 3.0 764 ± 87
RIC 106.2 ± 6.6 107.5 ± 6.5 67.8 ± 3.8 85.2 ± 5.1 976 ± 91 113.9 ± 4.4* 86.5 ± 4.6 50.0 ± 2.2 65.2 ± 3.0 647 ± 53
Table 2 Angiographic evaluation
n = 8–12/group
Isch ischemia only, IPreC ischemic preconditioning, IPostC ischemic postconditioning, RIC remote ischemic conditioning, LV left ventricle
APPROACH score
(% of LV)
TIMI score Myocardial blush grade TIMI myocardial perfusion grade
Isch 19.2 ± 2.2 2.4 ± 0.3 2.5 ± 0.3 2.3 ± 0.3
IPreC 18.6 ± 2.4 2.2 ± 0.3 2.4 ± 0.3 2.3 ± 0.3
IPostC 24.2 ± 2.2 1.8 ± 0.3 2.0 ± 0.4 2.0 ± 0.4
RIC 19.7 ± 2.5 2.3 ± 0.3 2.5 ± 0.3 2.5 ± 0.3
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reduced myocardial necrosis. Our results are in line with 
a number of ischemic conditioning studies in transla-
tional models or in clinical trials. IPostC/RIC has been 
shown to reduce myocardial necrosis after AMI in por-
cine models, although myocardial function was not dif-
ferent between groups [29, 46, 47]. Similarly, White et al. 
Fig. 3 The effect of IPreC, IPostC and RIC on myocardial necrosis (a; n = 5–6/group) and AAR (b; n = 5–6/group) as evaluated with conventional 
TTC and Evans blue staining. c Representative images of Evans blue/TTC-stained heart sections from three different hearts indicating myocardial 
necrosis and AAR (Each image was taken from the apical side of the third 1-cm slice. Images are optimized for visualization of TTC staining in the 
InfarctSize software.). Orange slice outline, green ventricular chamber, purple AAR, yellow myocardial necrosis. *p < 0.05 vs. Isch. Isch ischemia only, 
IPreC ischemic preconditioning, IPostC ischemic postconditioning, RIC remote ischemic conditioning, AAR area at risk, TTC triphenyl tetrazolium 
chloride, MRI LV left ventricle
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Table 3 Myocardial function as assessed by MRI
n = 4–8/group
Isch ischemia only, IPreC ischemic preconditioning, IPostC ischemic postconditioning, RIC remote ischemic conditioning, LV left ventricle, RV right ventricle, EDVI end-
diastolic volume index, ESVI end-systolic volume index, SVI stroke volume index, EF ejection fraction, COI cardiac output index
Isch IPreC IPostC RIC
HR (1/min) 96.26 ± 7.76 100.50 ± 5.06 103.11 ± 4.75 100.13 ± 5.07
LV EDVI (mL/kg) 3.63 ± 0.25 3.10 ± 0.02 3.55 ± 0.16 3.55 ± 0.09
LV ESVI (mL/kg) 2.07 ± 0.15 1.81 ± 0.14 1.99 ± 0.13 2.09 ± 0.17
LV SVI (mL/kg) 1.49 ± 0.11 1.29 ± 0.15 1.53 ± 0.07 1.40 ± 0.10
LV EF (%) 43.47 ± 1.67 41.64 ± 4.75 44.63 ± 1.55 41.55 ± 2.77
LV COI (L/min/kg) 0.15 ± 0.02 0.11 ± 0.01 0.16 ± 0.01 0.14 ± 0.02
RV EDVI (mL/kg) 2.86 ± 0.21 2.80 ± 0.18 2.43 ± 0.09 2.59 ± 0.10
RV ESVI (mL/kg) 1.40 ± 0.09 1.65 ± 0.05 1.24 ± 0.07 1.32 ± 0.08
RV SVI (mL/kg) 1.46 ± 0.15 1.15 ± 0.18 1.29 ± 0.07 1.28 ± 0.08
RV EF (%) 43.95 ± 2.43 40.63 ± 3.66 47.44 ± 2.89 47.42 ± 2.61
RV COI (L/min/kg) 0.14 ± 0.02 0.09 ± 0.01 0.13 ± 0.01 0.12 ± 0.01
Table 4 Cardiac function parameters measured by echocardiography before interventions and after 3 h of reperfusion
* p < 0.05 vs. corresponding baseline. n = 9–10/group
LV left ventricle, EDDI end-diastolic diameter index, ESDI end-systolic diameter index, FS fractional shortening, EF ejection fraction, EDVI end-diastolic volume index, 
ESVI end-systolic volume index, SVI stroke volume index, DMI diastolic mass index, SMI systolic mass index
Isch IPreC IPostC RIC
Baseline 3 h Baseline 3 h Baseline 3 h Baseline 3 h
LV EDDI (mm/kg) 1.46 ± 0.10 1.54 ± 0.06 1.54 ± 0.10 1.54 ± 0.08 1.46 ± 0.08 1.46 ± 0.11 1.32 ± 0.10 1.44 ± 0.16
LV ESDI (mm/kg) 1.02 ± 0.11 1.21 ± 0.06 1.17 ± 0.10 1.21 ± 0.07 1.06 ± 0.07 1.09 ± 0.14 0.89 ± 0.11 1.09 ± 0.18
LV FS (%) 31.48 ± 3.87 23.83 ± 3.85 24.50 ± 2.91 21.85 ± 1.59 27.88 ± 1.80 27.13 ± 6.28 33.47 ± 4.47 28.04 ± 3.69
LV EF (%) 58.78 ± 6.04 37.90 ± 3.66* 47.60 ± 4.58 44.00 ± 2.67 53.75 ± 2.93 48.29 ± 8.29 60.07 ± 5.89 51.13 ± 6.76
LV EDVI (mL/kg) 3.07 ± 0.34 3.37 ± 0.26 3.37 ± 0.43 3.52 ± 0.49 3.14 ± 0.31 3.21 ± 0.45 2.53 ± 0.42 3.26 ± 0.78
LV ESVI (mL/kg) 1.41 ± 0.31 1.67 ± 0.25 1.61 ± 0.28 2.14 ± 0.32 1.47 ± 0.19 1.80 ± 0.40 1.09 ± 0.33 2.10 ± 0.81
LV SVI (mL/kg) 1.66 ± 0.14 1.41 ± 0.09 1.76 ± 0.32 1.38 ± 0.23 1.67 ± 0.18 1.41 ± 0.20 1.44 ± 0.18 1.31 ± 0.16
LV DMI (g/kg) 4.90 ± 0.61 4.87 ± 0.52 5.78 ± 0.99 4.73 ± 0.73 4.11 ± 0.60 4.52 ± 0.36 4.80 ± 0.55 4.53 ± 0.50
LV SMI (g/kg) 4.91 ± 0.63 5.03 ± 0.75 6.63 ± 1.29 5.10 ± 0.97 4.51 ± 0.82 4.34 ± 0.50 4.56 ± 0.75 4.99 ± 0.83
Table 5 Cardiac function parameters measured by  echocardiography before  interventions and  after 3  days of  reperfu-
sion
n = 7–9/group
LV left ventricle, EDDI end-diastolic diameter index, ESDI end-systolic diameter index, FS fractional shortening, EF ejection fraction, EDVI end-diastolic volume index, 
ESVI end-systolic volume index, SVI stroke volume index, DMI diastolic mass index, SMI systolic mass index
Isch IPostC RIC
Baseline 3 days Baseline 3 days Baseline 3 days
LV EDDI (mm/kg) 1.50 ± 0.09 1.47 ± 0.14 1.55 ± 0.08 1.59 ± 0.10 1.44 ± 0.05 1.47 ± 0.03
LV ESDI (mm/kg) 1.07 ± 0.11 1.05 ± 0.11 1.12 ± 0.09 1.08 ± 0.07 1.00 ± 0.04 0.99 ± 0.04
LV FS (%) 29.07 ± 3.92 28.50 ± 2.70 28.10 ± 3.16 31.38 ± 2.26 30.33 ± 2.05 32.93 ± 2.21
LV EF (%) 54.93 ± 5.53 54.67 ± 3.87 54.14 ± 4.49 59.48 ± 2.76 57.67 ± 2.99 61.04 ± 3.07
LV EDVI (mL/kg) 3.04 ± 0.30 3.29 ± 0.31 3.24 ± 0.29 3.59 ± 0.44 2.74 ± 0.16 3.05 ± 0.11
LV ESVI (mL/kg) 1.44 ± 0.28 1.48 ± 0.16 1.56 ± 0.24 1.41 ± 0.18 1.25 ± 0.15 1.19 ± 0.10
LV SVI (mL/kg) 1.59 ± 0.11 1.62 ± 0.29 1.68 ± 0.14 2.18 ± 0.31 1.66 ± 0.14 1.86 ± 0.12
LV DMI (g/kg) 4.43 ± 0.29 3.53 ± 0.45 3.99 ± 0.43 4.12 ± 0.44 4.16 ± 0.31 4.03 ± 0.26
LV SMI (g/kg) 4.31 ± 0.25 3.94 ± 0.35 3.96 ± 0.36 4.36 ± 0.44 3.66 ± 0.30 4.19 ± 0.23
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demonstrated in a clinical trial that RIC did not improve 
early cardiac function after STEMI, while myocardial 
necrosis was significantly attenuated by RIC [9]. Fur-
thermore, it seems that early post-AMI cardiac function 
is not necessarily a good predictor for the future out-
come in ischemic conditioning translational studies: For 
instance, Munk et  al. showed that RIC does not influ-
ence cardiac function at day 1 after AMI, however, car-
diac function was improved at day 30 [48]. In summary, 
acute post-AMI myocardial function may be determined 
by many other facts than myocardial necrosis, such as, 
e.g., actual sympathetic tone, regional wall motion [49], 
collateral flow [50], transmurality of infarction [50].
Translational models of AMI have a major impor-
tance to develop interventions for the clinical practice 
[18, 51, 52]. For this purpose, pigs are excellent model 
animals, since their cardiac anatomy and cardiovascular 
physiology exhibit similarities to the human heart [53]. 
Although the pig is suitable for closed-chest experi-
mentation, the majority of the studies on the effect of 
ischemic conditioning on AMI was performed by using 
open-chest models [32, 54], and relatively few studies are 
available in closed-chest models. Previously, IPostC [55, 
56] and RIC [57, 58] have been shown to reduce myocar-
dial necrosis in closed-chest swine models of AMI. How-
ever, in our present experimental conditions, IPostC and 
RIC did not reduce myocardial necrosis, but the positive 
control IPreC did. The discrepancy between our results 
and those of others might be explained by the signifi-
cantly different perioperative medication and experi-
mental design. The abovementioned studies applied 
medications required only for the perioperative proce-
dures (e.g. anesthesia, pain control), however, the thera-
peutical management of AMI consists of other drugs as 
well. Here we treated animals with acetylsalicylic acid 
and clopidogrel according to the clinical guidelines [59, 
60]. However, it has been shown that COX-2 is an essen-
tial mediator of IPreC [61] and of IPostC [62], and that 
its blockade neutralizes the cardioprotective effect of late 
IPreC [63]. Similarly, clopidogrel, a P2Y12 antagonist, has 
been retrospectively shown to reduce cardiac necrosis 
and to decrease cardiovascular events after AMI in clini-
cal trials [64, 65], which might be attributed to its anti-
platelet activity and a direct cardioprotective effect. Yang 
et  al. demonstrated that IPostC did not further reduce 
infarct size when the P2Y12 antagonist, cangrelor-pre-
treatment was applied in rabbits [26]. However, cardio-
protection could be elicited by an extended, 8-cycle-long 
IPostC in closed-chest pigs pretreated with acetylsali-
cylic acid and clopidogrel [29]. These data indicate that 
to ensure translational value of animal studies it is essen-
tial to apply perioperative medication according to clini-
cal guidelines [66].
In our present study, anesthesia was maintained by 
isoflurane. It is well-documented that certain anaesthet-
ics, such as fluranes, induce cardioprotection [67] and/or 
interfere with cardioprotective interventions [68] making 
the assessment of the effect of conditioning stimuli more 
difficult. In our present study, we observed a decrease in 
myocardial necrosis by IPreC but not by IPostC and RIC 
with isoflurane anesthesia. Although studies showed car-
dioprotective efficacy of remote ischemic postcondition-
ing with the use of isoflurane [58], and of IPostC after a 
low-flow index ischemia with enflurane anesthesia in 
closed-chest porcine models [54], our results show no 
cardioprotection by IPostC and RIC. This discrepancy 
might be explained by significant differences between 
experimental protocols. In conclusion, there is a huge 
body of evidences that the application of antiplatelet 
drugs and inhalative anesthetics may interfere with vari-
ous conditioning maneuvres, although we did not specifi-
cally investigate them in our present study.
Although here we assessed the cardioprotective effect 
of IPostC and RIC as well as the positive control IPreC in 
a clinically relevant closed-chest pig model of AMI, this 
study has some limitations. It has been recently shown 
that the extent of myocardial edema has two peaks over 
time in swine [69], but not in humans [70]. Therefore, in 
this study alteration in myocardial edema at day 3 might 
not necessarily reflect attenuation of edema by condi-
tioning, but the altered dynamics of edema. A long-term 
follow up would provide data more relevant to the design 
of clinical studies. Therefore, here we could only specu-
late whether attenuation of myocardial edema by IPostC 
and RIC could be interpreted as a valid marker of the 
measure of IRI, or whether improved long-term outcome 
depends only on the reduction of myocardial necrosis. 
Although we did not measure myocardial edema directly 
(e.g., freeze-dry method), it is generally accepted that 
T2-hyperintensity correlates well with the myocardial 
water content, and T2-hyperintensity is excellent for 
tracking the differences in myocardial edema [19]. Fur-
thermore, according to the clinical routine, cardiac MRI 
was performed at day 3 [9], whereas ex vivo histopatho-
logical staining at 3 h of reperfusion according to the pre-
clinical standards [28]. Therefore, myocardial edema and 
definite AAR, i.e., Evans blue staining, were evaluated in 
separate groups. However, we calculated APPROACH 
score to estimate AAR in the same cohort, in which car-
diac MRI was performed. Although APPROACH score 
system has not been validated in pigs, it is most plau-
sible that it is suitable for the estimation of AAR in pig 
AMI experiments as well, since several anatomical stud-
ies demonstrated that the coronary anatomy of the pig 
shares a high similarity with that of the human heart (e.g., 
anastomoses, blood supply territory etc.) [53, 71].
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Conclusions
We compared the cardioprotective efficacy of IPostC and 
RIC and the positive control IPreC in a clinically relevant, 
closed-chest porcine model of reperfused AMI for the 
first time in the literature by using in  vivo MRI imaging 
and ex  vivo histology methods. IPostC and RIC did not 
decrease myocardial necrosis in our model, however, the 
positive control IPreC reduced it. The coronary microvas-
cular system has been protected by both IPostC and RIC 
as they attenuated myocardial edema, and IPostC reduced 
MVO. Our results indicate that parameters of microvas-
cular protection may be important to assess IRI and these 
parameters might change independently from that of myo-
cardial necrosis. Furthermore, since the intact microcir-
culation projects improved long-term outcome, its careful 
evaluation might help to avoid false negative results in pre-
clinical or clinical studies of cardioprotection.
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